The ESCRS congress will be held from September 6 to 10, 2024 in Barcelona.
OphtAI, an Evolucare Group subsidiary specializing in artificial intelligence for ophthalmology, will be presenting the latest developments in its retinal disease diagnosis solution.
Our booth: 6H05
OphtAI: one service, many gateways
OphtAI enables detection of the main pathologies with a retinal impact:
Diabetic retinopathy, diabetic macular edema, age-related maculopathy and macular degeneration, glaucoma.
It is available in a form integrated with retinographs and business software, with the company continually developing its partnerships and refining the functionalities available.
It is also available as an online service via the MyOphtai website. This enables ophthalmologists to submit their patients’ retinas directly, and obtain results without delay.
Finally, small applications, OphtAI Service and OphtAI App, complete these possibilities for users without integrations who want to save time by automating their processes. In this case, the application sends the images to the service and automatically retrieves the PDF report.
OphtAI is available as a monthly subscription for unlimited use. One month free of charge: come and see us at our stand to find out how!
A dozen pathologies to be detected soon
Our teams are working to extend the system’s detection capabilities, and from next year we expect to be able to detect nevi, cataracts, severe myopia, macular holes, epiretinal membranes, central and branch retinal vein occlusions, retinitis pigmentosa, diabetic syndrome and maternal inherited deafness (MIDD), and laser photocoagulation scars.
Our integration partners
Our scientific partners
Visit the congress site
Visit OPHTAI.COM
